Defibrillator After Primary Angioplasty - DAPA

Sep 03, 2019
Font Size
A
A
A
Author/Summarized by Author:
Anthony A. Bavry, MD, MPH, FACC
Summary Reviewer:
Deepak L. Bhatt, MD, MPH, MBA, FACC
Trial Sponsor:
Medtronic
Date Presented:
09/03/2019
Date Updated:
09/03/2019
Original Posted Date:
09/03/2019
References

Contribution To Literature:

The DAPA trial showed that early ICD after primary PCI may be beneficial at improving long-term survival.

Description:

The goal of the trial was to evaluate a prophylactic implantable cardioverter-defibrillator (ICD) compared with standard of care among patients who underwent primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).

Study Design

  • Randomized
  • Parallel

STEMI patients, 30-60 days after their event, were randomized to ICD (n = 129) versus standard of care (n = 133). The ICD was programmed to only give shocks for heart rate >190 bpm.

  • Total number of enrollees: 262
  • Duration of follow-up: 3 years

Inclusion criteria:

Primary PCI for STEMI and ≥1 high risk factor:

  • Left ventricular ejection fraction <30% within 4 days
  • TIMI flow <3 after primary PCI
  • Primary ventricular fibrillation
  • Killip class ≥2

Principal Findings:

The trial was terminated early due to slow enrollment.

The primary net outcome, all-cause mortality at 3 years, occurred in 24.4% of the ICD group compared with 35.5% of the standard care group (p = 0.02).

Interpretation:

Among STEMI patients who underwent primary PCI, early ICD implantation (within 30-60 days) in high-risk patients was beneficial. Early ICD implantation was associated with a reduction in all-cause mortality at 3 years compared with standard of care. High-risk characteristics that guided ICD implantation included early severe left ventricular systolic dysfunction (<30%) and impaired TIMI flow after primary PCI. Confirmatory studies are warranted.

References:

Presented by Dr. Danielle Marianne Haanschoten at the European Society of Cardiology Congress, Paris, France, September 3, 2019.

Engage with fellow ACC members by discussing this article and ESC Congress 2019 on ACC's Member Hub message board. Please log into ACC.org to participate. Not a member? Join the ACC today!

Keywords: ESC Congress, ESC 19, Acute Coronary Syndrome, Angioplasty, Anterior Wall Myocardial Infarction, Arrhythmias, Cardiac, Cardiology Interventions, Defibrillators, Implantable, Heart Failure, Myocardial Infarction, Percutaneous Coronary Intervention, Risk Factors, Secondary Prevention, Standard of Care, Stroke Volume, Ventricular Dysfunction, Left, Ventricular Fibrillation


< Back to Listings